Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed November 12, 2025.
- Filed
- Nov 12, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-277584
| Line item | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 |
|---|---|---|
| Proceeds from maturities of available-for-sale marketable securities | 306,500 | 174,300 |
| Internal-use software development costs capitalized in other non-current assets | (590) | — |
| Proceeds from sale of property and equipment | 70 | — |
| Purchases of property and equipment | (6) | (1,673) |
| Net cash provided by (used in) investing activities | 57,302 | (190,124) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock upon initial public offering, net of underwriting commissions | — | 341,171 |
| Proceeds from exercise of common stock options | 1,654 | 227 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s capex?
- Kyverna Therapeutics, Inc. (KYTX) reported capex of $2K in Q3 2025.
- How has Kyverna Therapeutics, Inc.'s capex changed year-over-year?
- Kyverna Therapeutics, Inc.'s capex decreased by 98.0% year-over-year, from $102K to $2K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Kyverna Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude